Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Dave Gray offers a solid, free Python tutorial that runs for about 9 hours. It’s a pretty methodical course, starting with the basics and moving into more complex stuff like closures and recursion. He ...

Some books move forward. Others circle. "Paradiso 17" by Hannah Lillith Assadi and "Python's Kiss" by Louise Erdrich belong ...

Cloudflare’s Dynamic Workers aim to simplify how enterprises execute AI-generated code, signaling a shift toward lightweight, ...

Threat actors abused trusted Trivy distribution channels to inject credential‑stealing malware into CI/CD pipelines worldwide ...

Karpathy's 'autoresearch' agent did not improve its own code, but it points towards systems that could as well as towards way to conduct other kinds of autonomous scientific research ...

安德烈·卡帕西（Andrej Karpathy）是人工智能领域最具影响力的实践者之一。他曾是OpenAI的创始成员、特斯拉的AI总监，如今以独立研究者的身份持续探索技术的前沿。在人工智能经历颠覆性跃迁的当下，卡帕西对这场变革的感知尤为敏锐。

一句话总结他的状态： 从 12 月开始就没手写过一行代码了，每天对着 Agent 说话 16 个小时，还觉得自己不够努力。 「AI 精神病」 Karpathy 说，他在 12 月的某个时刻经历了一个「翻转」。 从自己写 80%、Agent 写 20% ...